Prevalence, Intensity and Consequences of Bortezomib-induced Neuropathic Disorders.
- Status
- COMPLETED
- Phase
- N/A
Clinical Trials Related to Bortezomib
Related studies linked through entity extraction aliases.
Study of VTD in Waldenstrom's Macroglobulinemia
- Status
- UNKNOWN
- Phase
- PHASE2
A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis
- Status
- COMPLETED
- Phase
- PHASE3
MUK Nine b: OPTIMUM Treatment Protocol
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis
- Status
- WITHDRAWN
- Phase
- PHASE2
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide
- Status
- TERMINATED
- Phase
- PHASE2
Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3
Treatment of Adult-Onset Immunodeficiency With Bortezomib
- Status
- UNKNOWN
- Phase
- PHASE2
The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE2
A Single-center Clinical Trial of Bortezomib in Management of Immune Thrombocytopenia (ITP)
- Status
- UNKNOWN
- Phase
- PHASE2
2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy
- Status
- WITHDRAWN
- Phase
- PHASE2
Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment
- Status
- COMPLETED
- Phase
- PHASE2
Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA)
- Status
- UNKNOWN
- Phase
- PHASE1
A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2